Disclaimer:

Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.

Lamivudine

×

Overview

What is Lamivudine?

Lamivudine (also known as 3TC) is a synthetic nucleoside analogue with activity against HIV-1 and HBV. The chemical name of lamivudine is (-)-1-[(2,5)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl] cytosine. Lamivudine is the (-)enantiomer of a dideoxy analogue of cytidine. Lamivudine has also been referred to as (-)2′,3′-dideoxy, 3′-thiacytidine. It has a molecular formula of CHNOS and a molecular weight of 229.26 g per mol. It has the following structural formula:

Lamivudine, USP is a white to off-white crystalline powder with a solubility of approximately 70 mg per mL in water at 20°C.

Lamivudine tablets, USP are for oral administration. Each scored 150-mg film-coated tablet and each 300-mg film-coated tablet contains 150 mg or 300 mg of lamivudine, respectively and the inactive ingredients hypromellose, magnesium stearate, microcrystalline cellulose, propylene glycol, sodium starch glycolate (potato) and titanium dioxide.



What does Lamivudine look like?



What are the available doses of Lamivudine?

Lamivudine Tablets, USP are available containing 150 mg or 300 mg of lamivudine, USP.

What should I talk to my health care provider before I take Lamivudine?

 

How should I use Lamivudine?

Lamivudine tablets are a nucleoside analogue indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus type 1 (HIV-1) infection.

Limitations of Use:

The recommended dosage of lamivudine tablets in HIV-1-infected adults is 300 mg daily, administered as either 150 mg taken orally twice daily or 300 mg taken orally once daily with or without food. If lamivudine is administered to a patient infected with HIV-1 and HBV, the dosage indicated for HIV-1 therapy should be used as part of an appropriate combination regimen .


What interacts with Lamivudine?

Sorry No Records found


What are the warnings of Lamivudine?

Sorry No Records found


What are the precautions of Lamivudine?

Sorry No Records found


What are the side effects of Lamivudine?

Sorry No records found


What should I look out for while using Lamivudine?

Lamivudine tablets are contraindicated in patients with a previous hypersensitivity reaction to lamivudine.

†

®

†

®


What might happen if I take too much Lamivudine?

There is no known specific treatment for overdose with lamivudine. If overdose occurs, the patient should be monitored and standard supportive treatment applied as required. Because a negligible amount of lamivudine was removed via (4-hour) hemodialysis, continuous ambulatory peritoneal dialysis, and automated peritoneal dialysis, it is not known if continuous hemodialysis would provide clinical benefit in a lamivudine overdose event.


How should I store and handle Lamivudine?

Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature].Preserve in tight, light-resistant containers as defined in the USP.Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature].Preserve in tight, light-resistant containers as defined in the USP.Lamivudine Tablets, USP are available containing 150 mg or 300 mg of lamivudine, USP.The 150 mg tablets are white to off-white, film-coated, capsule shaped, functionally scored tablets debossed with on the left of the score and on the right of the score on one side of the tablet and on the left of the score and on the right of the score on the other side. They are available as follows:NDC 0378-5169-91bottles of 60 tabletsThe 300 mg tablets are white to off-white, film-coated, oval, unscored tablets debossed with on one side of the tablet and on the other side. They are available as follows:NDC 0378-5170-93bottles of 30 tabletsRecommended Storage: Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.]Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure.Lamivudine Tablets, USP are available containing 150 mg or 300 mg of lamivudine, USP.The 150 mg tablets are white to off-white, film-coated, capsule shaped, functionally scored tablets debossed with on the left of the score and on the right of the score on one side of the tablet and on the left of the score and on the right of the score on the other side. They are available as follows:NDC 0378-5169-91bottles of 60 tabletsThe 300 mg tablets are white to off-white, film-coated, oval, unscored tablets debossed with on one side of the tablet and on the other side. They are available as follows:NDC 0378-5170-93bottles of 30 tabletsRecommended Storage: Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.]Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure.Lamivudine Tablets, USP are available containing 150 mg or 300 mg of lamivudine, USP.The 150 mg tablets are white to off-white, film-coated, capsule shaped, functionally scored tablets debossed with on the left of the score and on the right of the score on one side of the tablet and on the left of the score and on the right of the score on the other side. They are available as follows:NDC 0378-5169-91bottles of 60 tabletsThe 300 mg tablets are white to off-white, film-coated, oval, unscored tablets debossed with on one side of the tablet and on the other side. They are available as follows:NDC 0378-5170-93bottles of 30 tabletsRecommended Storage: Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.]Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure.Lamivudine Tablets, USP are available containing 150 mg or 300 mg of lamivudine, USP.The 150 mg tablets are white to off-white, film-coated, capsule shaped, functionally scored tablets debossed with on the left of the score and on the right of the score on one side of the tablet and on the left of the score and on the right of the score on the other side. They are available as follows:NDC 0378-5169-91bottles of 60 tabletsThe 300 mg tablets are white to off-white, film-coated, oval, unscored tablets debossed with on one side of the tablet and on the other side. They are available as follows:NDC 0378-5170-93bottles of 30 tabletsRecommended Storage: Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.]Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure.Lamivudine Tablets, USP are available containing 150 mg or 300 mg of lamivudine, USP.The 150 mg tablets are white to off-white, film-coated, capsule shaped, functionally scored tablets debossed with on the left of the score and on the right of the score on one side of the tablet and on the left of the score and on the right of the score on the other side. They are available as follows:NDC 0378-5169-91bottles of 60 tabletsThe 300 mg tablets are white to off-white, film-coated, oval, unscored tablets debossed with on one side of the tablet and on the other side. They are available as follows:NDC 0378-5170-93bottles of 30 tabletsRecommended Storage: Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.]Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure.Lamivudine Tablets, USP are available containing 150 mg or 300 mg of lamivudine, USP.The 150 mg tablets are white to off-white, film-coated, capsule shaped, functionally scored tablets debossed with on the left of the score and on the right of the score on one side of the tablet and on the left of the score and on the right of the score on the other side. They are available as follows:NDC 0378-5169-91bottles of 60 tabletsThe 300 mg tablets are white to off-white, film-coated, oval, unscored tablets debossed with on one side of the tablet and on the other side. They are available as follows:NDC 0378-5170-93bottles of 30 tabletsRecommended Storage: Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.]Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure.Lamivudine Tablets, USP are available containing 150 mg or 300 mg of lamivudine, USP.The 150 mg tablets are white to off-white, film-coated, capsule shaped, functionally scored tablets debossed with on the left of the score and on the right of the score on one side of the tablet and on the left of the score and on the right of the score on the other side. They are available as follows:NDC 0378-5169-91bottles of 60 tabletsThe 300 mg tablets are white to off-white, film-coated, oval, unscored tablets debossed with on one side of the tablet and on the other side. They are available as follows:NDC 0378-5170-93bottles of 30 tabletsRecommended Storage: Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.]Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure.


×

Clinical Information

Chemical Structure

No Image found
Clinical Pharmacology

Lamivudine is an antiretroviral agent

Non-Clinical Toxicology
Lamivudine tablets are contraindicated in patients with a previous hypersensitivity reaction to lamivudine.

Cyclobenzaprine may have life-threatening interactions with MAO inhibitors (see ). Postmarketing cases of serotonin syndrome have been reported during combined use of cyclobenzaprine hydrochloride and other drugs, such as SSRIs, SNRIs, TCAs, tramadol, bupropion, meperidine, verapamil, or MAO inhibitors. If concomitant treatment with cyclobenzaprine hydrochloride and other serotonergic drugs is clinically warranted, careful observation is advised, particularly during treatment initiation or dose increases (see ).

Cyclobenzaprine hydrochloride may enhance the effects of alcohol, barbiturates, and other CNS depressants.

Tricyclic antidepressants may block the antihypertensive action of guanethidine and similarly acting compounds.

Tricyclic antidepressants may enhance the seizure risk in patients taking tramadol.

Array

Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogues and other antiretrovirals. A majority of these cases have been in women. Obesity and prolonged nucleoside exposure may be risk factors. Caution should be exercised when administering lamivudine to any patient with known risk factors for liver disease; however, cases also have been reported in patients with no known risk factors. Treatment with lamivudine should be suspended in any patient who develops clinical or laboratory findings suggestive of lactic acidosis or pronounced hepatotoxicity (which may include hepatomegaly and steatosis even in the absence of marked transaminase elevations).

The following adverse reactions are discussed in other sections of the labeling:

×

Reference

This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"

While we update our database periodically, we cannot guarantee it is always updated to the latest version.

×

Review

Rate this treatment and share your opinion


Learn about User Reviews

Helpful tips to write a good review:

  1. Only share your first hand experience as a consumer or a care giver.
  2. Describe your experience in the Comments area including the benefits, side effects and how it has worked for you. Do not provide personal information like email addresses or telephone numbers.
  3. Fill in the optional information to help other users benefit from your review.

Reason for Taking This Treatment

(required)

Click the stars to rate this treatment

Effectiveness (required)

This medication has worked for me.




Ease of Use (required)

This medication has been easy for me to use.




Satisfaction (required)

Overall, I have been satisfied with my experience.




Write a brief description of your experience with this treatment:

2000 characters remaining

Optional Information

Help others benefit from your review by filling in the information below.
I am a:
Gender:
×

Professional

Clonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72
×

Tips

Tips

×

Interactions

Interactions

A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).